2c-t-13 2c-t-13 2c-t-13 (2,5-dimethoxy-4-(β-methoxyethylthio)phenethylamine) is a psychedelic phenethylamine of the 2c family. it was presumably first synthesized by alexander shulgin and reported in his book pihkal. 2c-t-13 names preferred iupac name 2-ethan-1-amine identifiers cas number 207740-30-5 n 3d model (jsmol) interactive image chembl chembl123868 y chemspider 21106228 y pubchem cid 44350108 unii sk8jcs3s9b n comptox dashboard (epa) dtxsid10658379 inchi inchi=1s/c13h21no3s/c1-15-6-7-18-13-9-11(16-2)10(4-5-14)8-12(13)17-3/h8-9h,4-7,14h2,1-3h3 ykey: pyjlrnogmkmrtk-uhfffaoysa-n yinchi=1/c13h21no3s/c1-15-6-7-18-13-9-11(16-2)10(4-5-14)8-12(13)17-3/h8-9h,4-7,14h2,1-3h3key: pyjlrnogmkmrtk-uhfffaoyas smiles coc1cc(sccoc)c(cc1ccn)oc properties chemical formula c13h21no3s molar mass 271.38 g·mol−1 except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). n verify (what is yn ?) infobox references chemistry the drug has structural properties similar to mescaline and other drugs in the 2c-t series, with the most closely related compounds being 2c-t-7 and 2c-t-21. general information the dosage range of 2c-t-13 is typically 25 - 40 mg and its duration is approximately 6–8 hours according to shulgin. 2c-t-13 produces many closed-eye visuals and geometric patterns. it also produces slight visual distortion. pharmacology the mechanism that produces 2c-t-13's hallucinogenic and entheogenic effects has not been specifically established; however, it is most likely to result from action as a 5-ht2a serotonin receptor agonist in the brain, a mechanism of action shared by all of the hallucinogenic tryptamines and phenethylamines for which the mechanism of action is known. dangers the toxicity of 2c-t-13 is not well documented. 2c-t-13 is slightly less potent than 2c-t-7, but it may be expected that at higher doses it would display similar toxicity to that of other phenethylamines of the 2c-t family. legality 2c-t-13 is not scheduled in the united states, but possession and sales of 2c-t-13 could be prosecuted under the federal analog act because of its structural similarities to 2c-t-7. as of october 31, 2016, 2c-t-13 is a controlled substance (schedule iii) in canada.